NCT00053924已完成2 期
A Phase 2 Study Of Perifosine As Second Line Therapy For Advanced Pancreatic Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 6
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced or metastatic pancreatic cancer.
详细描述
OBJECTIVES:
- Determine the efficacy of perifosine, in terms of 6-month survival, in patients with advanced adenocarcinoma of the pancreas.
- Determine the safety and tolerability of this drug in these patients.
- Determine median survival time and the 1-year survival rate of patients treated with this drug.
- Determine the objective response rate (partial and complete), response duration, and time to progression in patients treated with this drug.
- Determine the toxicity of this drug in these patients.
OUTLINE: Patients receive oral perifosine daily for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 17-37 patients will be accrued for this study within 15 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Perifosine in Treating Patients With Metastatic or Recurrent Malignant MelanomaMelanoma (Skin)NCT00053781NCIC Clinical Trials Group18
已完成
2 期
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue SarcomaEndometrial CancerSarcomaNCT00053794NCIC Clinical Trials Group17
已完成
2 期
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast CancerBreast CancerNCT00054145University Health Network, Toronto
已完成
2 期
Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate CancerProstate CancerNCT00060437National Cancer Institute (NCI)
已完成
1 期
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic CancerMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnspecified Adult Solid Tumor, Protocol SpecificLymphomaLeukemiaNCT00019656National Cancer Institute (NCI)